Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Hernán’s appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based ...

Osaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub and HyHub ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, ...

Kenshi (Kenjustsu) vs Takeda (Shirai Ryu) Me Second Fight: 3:14 Takeda (Shirai Ryu) Me vs Shinnok (Imposter) Third Fight: ...